Less of an issue [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2010-02-01 16:29 (5616 d 14:46 ago) – Posting: # 4684
Views: 24,477

Goede middag d_labes,

❝ Regarding the fixed effects issue you questioned above in your post:

❝ I can't imagine, what this means at all :ponder:, especially if I think about the sequence test. Shall we use the error term as the denominator as is in a fully fixed effects model?

❝ We all know that this is the wrong (already Grizzle in his basic paper noticed the right denominator is the subject(sequence) MS).


This I don't think is an issue at all. Even in spite of the bogus statement, Proc Glm fits the entire model as a fixed effects model, which is good enough for 2-seq 2-per 2-trt data. So even though subject in such a design is treated as fixed, it does not imply that the seq effect cannot be tested using the between subject variabilty in the denominator. This is to the best of my knowledge what the bogus statement allows for and does post-hoc, and this is compliant with the guideline's wording.

EM.

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,675 registered users;
40 visitors (0 registered, 40 guests [including 13 identified bots]).
Forum time: 08:16 CEST (Europe/Vienna)

Philosophy, like medicine, has plenty of drugs, few good remedies,
and hardly any specific cures.    Sebastien-Roch Nicolas de Chamfort

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5